Using BCR-ABL Transcript Levels After 3 Months of Therapy on Imatinib is the Best Way to Predict Long-Term Outcome for Patients with CML Treated with Imatinib
Episode Description
The study by Marin et al is another milestone in our understanding how to manage CML patients on tyrosine kinase inhibitors.

























